drugset / Trial / NCT04202536

Switching From Tenofovir Disoproxil Fumarate to Besifovir Dipivoxil Maleate

NCT04202536

Phase 4 Unknown 152 enrolled IlDong Pharmaceutical Co Ltd
RandomizedParallel-groupOpen-labelTreatment

Summary

A research study to observe the safety, efficacy and tolerability of switching from Tenofovir Disoproxil Fumarate to Besifovir dipivoxil maleate in patients with chronic hepatitis B

Timeline

Start
2019-05-29
Primary completion
2021-06
Completion
2021-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Besifovir Other / unclassified 150 mg
Comparator Tenofovir disoproxil fumarate Small molecule 300 mg Oral
Background L-carnitine Other / unclassified 660 mg